InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.465 0.005 (1.06%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$223 Starpharma signs agreement with Unilever 7 Apr 2008 9:25AM $0.270 $0.465 risen by 72.22%
$223 Half Yearly Report and Accounts 21 Feb 2008 11:06AM $0.300 $0.465 risen by 55%
$223 Appendix 4C - quarterly 31 Jan 2008 10:12AM $0.350 $0.465 risen by 32.86%
$223 Expansion of VivaGel US trial and enrollment completion 8 Jan 2008 11:32AM $0.380 $0.465 risen by 22.37%
$223 Signs collaborative research agreement with Stiefel Labs Inc 3 Dec 2007 11:56AM $0.370 $0.465 risen by 25.68%
$223 Appendix 4C - quarterly 31 Oct 2007 1:45PM $0.435 $0.465 risen by 6.90%
$223 Arterial disease imaging agent funding to SPL and Baker 31 Oct 2007 8:38AM $0.410 $0.465 risen by 13.41%
$223 Co-development agreement with Durex for condoms with VivaGel 16 Oct 2007 9:21AM $0.420 $0.465 risen by 10.71%
$223 Preliminary Final Report 29 Aug 2007 1:47PM $0.365 $0.465 risen by 27.40%
$223 US Institution Platinum Partners LLC invests in Starpharma 21 Aug 2007 9:58AM $0.335 $0.465 risen by 38.81%
$223 Starpharma`s DNT to develop water purification technology 8 Aug 2007 11:32AM $0.390 $0.465 risen by 19.23%
$223 Appendix 4C - quarterly 31 Jul 2007 11:53AM $0.375 $0.465 risen by 24%
$223 Presents Positive Results of VivaGel Male Clinical Study 24 Jul 2007 8:31AM $0.400 $0.465 risen by 16.25%
$223 Signs Agreement for Condom Coating Application of VivaGel 18 Jul 2007 9:20AM $0.430 $0.465 risen by 8.14%
$223 U.S. Trial of VivaGel Commences 10 Jul 2007 9:11AM $0.390 $0.465 risen by 19.23%
$223 Priostar Dendrimer Improve Fluorescence Properties 7 May 2007 10:26AM $0.420 $0.465 risen by 10.71%
$223 Commitments Test Entity - Third Quarter Report 30 Apr 2007 9:14AM $0.400 $0.465 risen by 16.25%
$223 Half Yearly Report & Half Year Accounts 23 Feb 2007 11:47AM $0.500 $0.465 fallen by 7%
$223 DNT & EMD Biosciences sign license & supply agreement 19 Feb 2007 9:58AM $0.510 $0.465 fallen by 8.82%
$223 NIH funds further clinical development of VivaGel 13 Feb 2007 10:24AM $0.470 $0.465 fallen by 1.06%
$223 VivaGel Clinical Trials Proceeding as Planned 2 Feb 2007 12:53PM $0.460 $0.465 risen by 1.09%
$223 Commitments Test Entity - Second Quarter Report 31 Jan 2007 9:41AM $0.470 $0.465 fallen by 1.06%
$223 VivaGel Market Update 13 Nov 2006 3:32PM $0.510 $0.465 fallen by 8.82%
$223 Commitments Test Entity - First Quarter Report 31 Oct 2006 12:00PM $0.580 $0.465 fallen by 19.83%
$223 US Clinical Trial of VivaGel for Genital Herpes Commences 24 Oct 2006 11:04AM $0.590 $0.465 fallen by 21.19%

826 - 850 of 901 results

Page 34 of 37

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.